Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Hims & Hers vs TOM Weight Loss

Two GLP-1 desks, one scoreboard. We put Hims & Hers and TOM Weight Loss head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 26 · Grade B

Hims & Hers

Visit Hims & Hers Full brief →

FDA warning letter, September 2025 — issued to Hims & Hers Health, Inc. dba Hims. See the FDA's warning letter database.

vs
No. 67 · Grade C

TOM Weight Loss

Visit TOM Weight Loss Full brief →

The verdict

Hims & Hers takes this head-to-head.

Hims & Hers scores 85 to 77 on our six-factor Brief Score — Mass-market, app-first weight program with nationwide reach — watch the compounded-supply headlines.

That doesn't make TOM Weight Loss a bad call — it's best for readers who want texas or utah patients wanting direct abom-certified physician access at competitive flat-rate pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
83
78
Supply Reliability
86
75
Transparency
83
88
Access Breadth
88
56
Clinical Oversight
86
91
Track Record
86
73
Hims & HersBrief Score 85 · 77TOM Weight Loss

Price, coverage & the tracker

Hims & HersTOM Weight Loss
Brief Score85/100 (B)77/100 (C)
Semaglutide$199/moFrom $199/mo (all doses, compounded)
TirzepatideNot disclosedFrom $249/mo (all doses, compounded)
CoverageAll 50 states2 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerRisingprice risingNewnew to the tracker, no prior reading

Hims & Hers: App-first reach is nationwide, but compounded supply has drawn industry-wide scrutiny.

TOM Weight Loss: New to the tracker on 1 August 2026. The published line reads From $199/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.